UAE delegation visits Japan to strengthen cooperation in advanced radiotherapy
TOKYO 2025 (WAM)A high-level delegation from the United Arab Emirates, comprising representatives from the Federal Authority for Nuclear Regulation (FANR) and Cleveland Clinic Abu Dhabi, conducted an official visit to Japan to enhance bilateral cooperation in advanced radiotherapy—particularly heavy ion therapy—as well as in related regulatory, healthcare, and research practices.Led by the Director-General of FANR, Christer Viktorsson, the visit aimed to gain in-depth insights into Japan's leadership in heavy ion therapy, including regulatory frameworks, operational practices, safety protocols, and training programs required to build national capacity for utilising such technologies.During the visit, the UAE delegation held high-level meetings and technical exchanges with key Japanese institutions, including Yamagata University's Heavy Ion Medical Center, the National Institutes for Quantum Science and Technology (QST), the Nuclear Regulation Authority (NRA), and Nuclear Damage Compensation and Decommissioning Facilitation Corporation.The visit follows the UAE's recent announcement to establish the region's first heavy ion therapy centre at Cleveland Clinic Abu Dhabi, a landmark initiative that underscores the country's commitment to advancing cancer care and positioning Abu Dhabi as a hub for world-class oncology services.Viktorsson said, 'This visit reflects FANR's commitment to ensuring the safe and effective use of radiation in medicine through global collaboration. Japan's experience in advanced radiotherapy and regulatory oversight offers valuable lessons that will help realise the UAE's vision of becoming a leader in healthcare innovation, strengthening its knowledge-based economy, and promoting medical tourism. Integrating such state-of-the-art technologies enhances the UAE's global standing in both healthcare and scientific research.'Heavy ion therapy is an advanced form of radiotherapy known for its precision and efficacy. It delivers high doses of radiation directly to cancer cells while minimising damage to surrounding healthy tissue. The treatment is especially effective for inoperable or treatment-resistant tumours, such as large cancers or liver metastases, and is associated with reduced treatment frequency and lower risk of secondary cancers.The UAE delegation's discussions also covered regulatory licensing and oversight requirements, safety and operational standards, and the training frameworks needed to ensure a skilled workforce capable of safely managing such sophisticated technologies.
This visit forms part of FANR's ongoing efforts to strengthen international cooperation and uphold the highest standards of safety, security, and transparency in the UAE's nuclear and radiation sectors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hi Dubai
4 days ago
- Hi Dubai
ASICS Sponsors Six UAE Athletes to Compete at the World Transplant Games 2025
In a milestone moment for sport and healthcare in the region, ASICS is proudly sponsoring six extraordinary athletes from the UAE as they gear up to compete at the World Transplant Games 2025 in Dresden, Germany. Taking place this August, the Games bring together transplant recipients and living donors from around the world, and for the first time, the UAE will be represented on that global stage. The World Transplant Games is more than a sporting event, it's a global tribute to strength, spirit, and second chances. Bringing together thousands of transplant recipients, living donors, and their loved ones, the Games spotlight the life-saving impact of organ donation and the extraordinary role movement plays in healing both body and mind. ASICS is proudly championing six inspiring individuals from the UAE, each a powerful testament to resilience, recovery, and the unifying force of sport. Rooted in the Japanese philosophy Anima Sana In Corpore Sano ("A Sound Mind in a Sound Body"), ASICS has long championed sport as a pathway to mental and physical wellbeing. This sponsorship further reinforces the brand's commitment to inclusive performance, purpose-led innovation, and movement as medicine. The initiative aligns closely with ASICS' global values as a caregiver brand that supports individuals at every stage of their journey through sport. The UAE team includes: Katie Larkins – Liver transplant recipient and educator leading Team UAE while competing in long-distance races, advocating for organ donation and youth wellness. – Liver transplant recipient and educator leading Team UAE while competing in long-distance races, advocating for organ donation and youth wellness. Omar 'OT' Tom – Two-time kidney transplant recipient and sprinter using his story to inspire a new generation of transplant athletes. – Two-time kidney transplant recipient and sprinter using his story to inspire a new generation of transplant athletes. Fatima Rashid – Kidney transplant recipient and mental health advocate competing in multiple events to spotlight strength through movement. – Kidney transplant recipient and mental health advocate competing in multiple events to spotlight strength through movement. Justin Anthony – Double lung transplant recipient embracing a second chance at life through competitive throwing and bowling events. – Double lung transplant recipient embracing a second chance at life through competitive throwing and bowling events. Husena Beguwala – Filmmaker and lung transplant survivor running to raise awareness for rare diseases and the power of organ donation. – Filmmaker and lung transplant survivor running to raise awareness for rare diseases and the power of organ donation. Hind Juma – Hind Juma – Living kidney donor whose journey of love, resilience, and perseverance led to saving her mother's life; now back on track and proudly representing the UAE at the World Transplant Games. This initiative forms part of ASICS' wider sustainability and innovation roadmap, extending beyond materials and product design to how the brand empowers communities, champions mental wellbeing, and fosters real-world impact through meaningful partnerships. By backing Team UAE, ASICS aims to inspire individuals across the region to move for their minds, bodies, and communities, while honoring those who prove that every step forward is a triumph of purpose, resilience, and heart. Source: Empyre Communications
Al Etihad
5 days ago
- Al Etihad
Cleveland Clinic Abu Dhabi introduces aquablation therapy for Benign Prostatic Hyperplasia
6 Aug 2025 12:26 ABU DHABI (ALETIHAD)In a groundbreaking advancement for prostate treatment, Cleveland Clinic Abu Dhabi has introduced aquablation therapy, a cutting-edge, minimally invasive procedure that brings new hope for men suffering from Benign Prostatic Hyperplasia (BPH). This innovative therapy is the first in the UAE to use a robotic-assisted waterjet solution for BPH, providing a new benchmark in precision and safety through real-time ultrasound guidance and robotic control, without the potential risks associated with heat-based to global studies, nearly 50% of men over the age of 60 are affected by BPH, with the prevalence rising to around 80% by age 85. The condition can lead to frequent urination, weak urinary flow, and, in advanced cases, urinary retention or incontinence, significantly impacting a patient's quality of life. Traditional treatments like medication and Transurethral Resection of the Prostate (TURP) surgery, which removes excess prostate tissue, may involve longer recovery periods and potential side effects in some cases. Aquablation offers a minimally invasive, heat-free alternative with faster recovery and a lower risk of side on the adoption, Dr. Georges-Pascal Haber, Chief Executive Officer at Cleveland Clinic Abu Dhabi, and a leading urologist specialising in robotic surgery, said: 'At Cleveland Clinic Abu Dhabi, we are committed to continuously advancing our medical capabilities and ensuring that the latest technologies, like the aquablation therapy, are available to our patients." He added, "It represents another milestone in our pursuit of providing the highest standards of care to our patients. We are deeply grateful for the ongoing support from the Department of Health- Abu Dhabi, which enables us to deliver world-class healthcare solutions right here in Abu Dhabi.' Dr. Waleed Hassen, Department Chair of Urology in the Surgical Subspecialties Institute at Cleveland Clinic Abu Dhabi, added: 'Aquablation therapy represents a new era in the treatment of benign prostatic hyperplasia (BPH), addressing the limitations of traditional techniques with remarkable precision and safety. We chose to bring this technology to Cleveland Clinic Abu Dhabi because it aligns with our mission of providing the most advanced, patient-centred care. Unlike conventional methods, aquablation is ideal for patients with even the most challenging prostate conditions, offering a level of customisation and predictability that has not been possible before.'Aquablation therapy utilises the AquaBeam® Robotic System, which delivers a heat-free, high-pressure waterjet to precisely remove prostate tissue. Unlike traditional methods that use heat (such as laser or electrocautery-based techniques), the non-thermal waterjet technology ensures minimal damage to surrounding tissues, significantly lowering the risk of side effects such as incontinence or sexual treatment is guided by real-time ultrasound imaging and cystoscopy, which allow the surgeon to visualise critical structures, such as the bladder neck, verumontanum, and external sphincter, ensuring their preservation. This combination of robotic precision and advanced imaging helps optimise outcomes and minimise risks. Dr. Zaki Almallah, Staff Physician, Urology, Surgical Subspecialties Institute, Cleveland Clinic Abu Dhabi, explained: "Aquablation therapy is truly revolutionary in treating benign prostatic hyperplasia. It is a one-time procedure that provides long-lasting symptom relief, with patients enjoying the benefits for years after treatment. By harnessing the power of robotic technology, we can now offer patients a treatment that is both highly effective and minimally invasive. It's the only treatment that provides real-time imaging of the entire prostate, allowing us to precisely remove excess tissue while preserving reproductive function. This means patients experience fewer side effects, faster recovery and a significant improvement in quality of life."Dr. Omer Raheem, Staff Physician, Urology, Surgical Subspecialties Institute, Cleveland Clinic Abu Dhabi, added: 'The robotic precision in the aquablation is truly transformative, especially for patients with larger prostates where traditional methods often fall short. The average resection time with aquablation is just 5.8 minutes, compared to nearly half an hour for TURP, without compromising on safety or effectiveness. It's an advanced solution that minimises risk, accelerates recovery, and offers patients an unmatched standard of care.'Cleveland Clinic Abu Dhabi's introduction of aquablation therapy is a testament to offering advanced treatment, aligning with its mission to deliver world-class, innovative healthcare solutions. As part of its Urology Program, which already provides a wide range of surgical and non-surgical treatments for complex bladder, kidney, and prostate conditions, the addition of aquablation further enhances the hospital's comprehensive care offering. In addition to aquablation therapy, Cleveland Clinic Abu Dhabi recently introduced Focal One High-Intensity Focused Ultrasound (HIFU) for prostate cancer, a non-invasive procedure that uses ultrasound waves to target and destroy cancer cells with high precision. These advances highlight Cleveland Clinic Abu Dhabi's leadership in urological care, offering patients in the UAE access to cutting-edge treatments that significantly improve outcomes and quality of life. Source: Aletihad - Abu Dhabi
Al Etihad
6 days ago
- Al Etihad
Japan firm seeks approval for stem cell treatment for Parkinson's
TOKYO (AFP) Japanese drugmaker Sumitomo Pharma said Tuesday it is seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain, following a successful clinical trial. The company applied to Japanese regulators for manufacturing and marketing authorisation aimed at the treatment of patients with avanced Parkinson's disease, it said in a statement. A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells -- which have the potential to develop into any cell in the body -- was safe and successful in improving symptoms. The study involved seven Parkinson's patients aged between 50 and 69, with each receiving a total of either five million or 10 million cells implanted on both sides of the brain. The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease. The patients were monitored for two years and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said. The trial results were published in Nature in April. Sumitomo Pharma is also carrying out a clinical trial in the United States. Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement. Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation. Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation says. iPS cells are created by stimulating mature, already specialised, cells back into a juvenile state -- basically cloning without the need for an embryo. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
